Relievant Medsystems

Relievant Medsystems

A company that develops therapies to relieve patients with chronic back pains

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

June 8, 2020

Relievant Medsystems announces European Spine Journal publication of long-term data from the Level.

March 28, 2012

Relievant Medsystems raises a $30,000,000 series D round from Canaan Partners, Emergent Medical Partners, New Enterprise Associates, Morgenthaler Ventures and ONSET Ventures.

July 7, 2009

Relievant Medsystems raises a $20,000,000 series C round from ONSET Ventures, Morgenthaler Ventures, Canaan Partners and Emergent Medical Partners.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
2 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Justin Klein

Board member

Justin Klein

Investor

Samit Patel

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
June 8, 2020
BioSpace
Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term study i is a single-arm, open-label, prospective follow-up of 100 US pati

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.